about
Therapeutic options for management of endometrial hyperplasiaGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsAntitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsThe mutational landscape of endometrial cancerThe emerging genomic landscape of endometrial cancer.Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11AFrequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma.Hormonal and reproductive risk factors for sporadic microsatellite stable and unstable endometrial tumors.PI3K pathway dependencies in endometrioid endometrial cancer cell lines.The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and ReproducibilityNext-Generation Sequencing of Tubal Intraepithelial CarcinomasUse of mutation profiles to refine the classification of endometrial carcinomas.Obesity is associated with higher 4E-BP1 expression in endometrial cancer.Loss of Mismatch Repair Protein Expression in Unselected Endometrial Adenocarcinoma Precursor Lesions.Identification of long non-coding RNAs biomarkers associated with progression of endometrial carcinoma and patient outcomes.Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma.Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach.An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations.Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer.Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too LateClinicopathologic Features and Treatment Outcomes in Patients with Stage I, High-Risk Histology or High-Grade Endometrial Cancer after Primary Staging Surgery: A Taiwanese Gynecologic Oncology Group Study
P2860
Q26783569-0317CF13-9229-4887-AFD2-48634D84DB4BQ26998790-7E983E4F-9DB7-43D9-BA18-02FB1C20990FQ27853244-7BC2911B-E36C-43F3-9E36-0EE208B60A9DQ28084466-9759CCD4-14FA-4EFF-B250-53F7990DF66CQ34026976-95001034-CBD8-4EC7-9AEE-C49DC6A75C61Q34350701-3E16FE1C-08C0-417E-A086-D80EE82C8C9CQ34765551-9DEF317B-2D9F-4242-A89B-9E282D7EA99DQ34991225-D062F791-E418-4B34-8D9F-61E327E427B7Q35568234-C6C0411A-724A-4F33-9AE0-5E452F7331CEQ36980561-09F17170-9949-4C6A-AA12-5BA8B575804CQ37068930-ABAB8C76-9A98-496B-8A79-08475D018312Q37072893-197E09CB-3E60-4FCD-992E-ECAD16B06DDAQ37612253-2C4F1200-A18B-4EE2-A2F6-A4B4D14A8F74Q37638808-C9824B93-99B5-4FEA-8F98-90F39B5D13ABQ38710498-CFEF5E8D-0EC1-4C26-94DE-07B0F911A491Q41592814-75C61172-F4D8-4F62-9A26-60DDC57948EFQ41923500-3E2ABF1D-AF43-41E6-A5FE-023598A6EC18Q42030378-CE4C5834-52DE-4A44-8E3B-EFAA6B2AE370Q45848384-91D18520-F955-4539-AD77-480AE85C7A8FQ47097100-B05CB65C-A97F-4662-B332-56284F2DE9B3Q47140946-E8A9E61A-B8CE-4C21-8A73-88FF33110514Q53689778-7D80B20B-5B94-4F21-8825-BA932432658CQ54976636-F618B806-79E9-416B-99FA-E7F3E43E0383Q55278788-6DF8CBA5-525F-4B09-9BEC-9A88651C8B6BQ55553003-340C8650-C020-4606-BFBC-BA98278EC17DQ57169683-88B1F23D-480A-4DDC-BD3D-C4B091F1E748Q58764267-803A2149-3692-446D-8DB4-89125DDD7394
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The genomics and genetics of endometrial cancer.
@ast
The genomics and genetics of endometrial cancer.
@en
type
label
The genomics and genetics of endometrial cancer.
@ast
The genomics and genetics of endometrial cancer.
@en
prefLabel
The genomics and genetics of endometrial cancer.
@ast
The genomics and genetics of endometrial cancer.
@en
P2860
P356
P1476
The genomics and genetics of endometrial cancer.
@en
P2093
Andrea J O'Hara
Daphne W Bell
P2860
P356
10.2147/AGG.S28953
P577
2012-03-01T00:00:00Z